CSIMarket Company Name, Ticker, Customers, else..
 
Iveric Bio Inc   (ISEE)
Other Ticker:  
 
 
Price: $39.9500 $0.15 0.377%
Day's High: $39.99 Week Perf: 1.09 %
Day's Low: $ 39.85 30 Day Perf: 2.96 %
Volume (M): 10,999 52 Wk High: $ 39.99
Volume (M$): $ 439,414 52 Wk Avg: $28.05
Open: $39.86 52 Wk Low: $18.25



 Market Capitalization (Millions $) 5,477
 Shares Outstanding (Millions) 137
 Employees 91
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -223
 Cash Flow (TTM) (Millions $) 276
 Capital Exp. (TTM) (Millions $) 1

Iveric Bio Inc
Iveric Bio Inc is a publicly traded biopharmaceutical company that is focused on the development of innovative treatments for patients suffering from diseases affecting the retina of the eye. The company is headquartered in New York City, New York, and has research and development facilities in Durham, North Carolina.

Iveric Bio Inc is driven by a mission to develop innovative therapies that address unmet medical needs of patients suffering from rare and serious ophthalmic diseases. The company's primary area of focus is on developing treatments for age-related macular degeneration, a leading cause of blindness in the elderly population.

The company's lead product candidate, Zimura, is an investigational complement factor C5 inhibitor for the treatment of geographic atrophy, a severe form of dry age-related macular degeneration. Zimura is designed to eliminate the alternative complement pathway hyperactivation that is responsible for retinal cell death, which is the underlying cause of geographic atrophy.

Iveric Bio Inc leverages its proprietary understanding of the complement system, and has invested heavily in the discovery and development of complement inhibitors that target specific complement pathway components. The company is actively researching additional complement inhibitors that may be useful in treating a variety of ophthalmic diseases.

In addition to its focus on age-related macular degeneration, Iveric Bio Inc is exploring the potential of gene therapy and stem cell therapy in the treatment of inherited retinal diseases such as Stargardt disease and Leber congenital amaurosis.

Overall, Iveric Bio Inc is driven by a commitment to utilizing the latest advances in science and technology to develop innovative and effective treatments for patients suffering from ophthalmic diseases. The company remains firmly dedicated to conducting world-class research and clinical trials, and collaborating with top-tier academic institutions and industry leaders to advance the development of ophthalmic treatments that have the potential to improve the lives of millions of patients around the world.


   Company Address: 8 Sylvan Way Parsippany, 7054 NJ
   Company Phone Number: 474-6755   Stock Exchange / Ticker: NASDAQ ISEE
   ISEE is expected to report next financial results on February 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.
Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.
Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season



As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.
Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery



As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com